Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
Japan should build an NHI price revision rule that would swiftly reflect the declines in manufacturers’ shipment prices to reimbursement prices while ensuring appropriate margins for each healthcare stakeholder, pharma industry leader Sunao Manabe told Jiho on September 1. In…
To read the full story
Related Article
- Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
- JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
- New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
- JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…